Newman Ferrara LLP has begun an investigation into potential claims against the Board of Directors of InterMune, Inc. (“InterMune”) (NASDAQ: ITMN) concerning its proposed sale to Roche Holdings, Inc.
Under the terms of the proposed transaction valued at approximately $8.3 billion, Roche will commence a tender offer no later than August 29, 2014 to acquire all outstanding shares of InterMune common stock. InterMune stockholders will receive $74.00 in cash for each share of InterMune stock owned. The 52-week trading high of InterMune common stock is $73.19 per share.
Newman Ferrara’s investigation concerns whether InterMune’s Board of Directors has breached its fiduciary duties to act in the best interests of InterMune’s stockholders. The investigation focuses on the process by which InterMune’s Board of Directors considered and approved the proposed deal.
Concerned investors may contact Newman Ferrara attorney Roy Shimon at
to discuss this investigation, their rights, or potential remedies.
Newman Ferrara maintains a multifaceted practice based in New York City with attorneys specializing in complex commercial and multi-party litigation, securities fraud and shareholder litigation, consumer protection, civil rights, and real estate. For more information, please visit the firm website at
CONTACT:Newman Ferrara LLPRoy Shimon1250 Broadway, 27
Fl.New York, NY 10001